Side Effects of Tiotropium (Tropia) Inhaler
Tiotropium is generally well-tolerated with a safety profile similar to placebo, except for typical anticholinergic effects like dry mouth, constipation, and urinary difficulties, which are the most common side effects. 1, 2
Common Anticholinergic Side Effects
- Dry mouth is the most frequently reported side effect of tiotropium, occurring more commonly than with placebo 2, 3
- Urinary tract infections and urinary difficulties (retention, hesitancy) occur at increased rates compared to placebo 2, 3
- Constipation is another expected anticholinergic effect that occurs with tiotropium use 2
Cardiovascular Considerations
The cardiovascular safety profile of tiotropium shows mixed evidence:
- A large pooled analysis of 26 trials (17,014 patients) demonstrated that tiotropium was associated with a reduced risk of cardiac adverse events and major adverse cardiovascular events compared to placebo 2
- However, a 2022 Korean nationwide cohort study found that tiotropium increased the risk of coronary heart disease in patients aged 55 years and older (adjusted HR 1.24), particularly in the high cumulative exposure group and in never-smokers 4
- Tachycardia can occur, especially with overdose or in patients with atrial fibrillation, renal impairment, or underlying structural heart disease 5
Clinical Pitfall
When prescribing tiotropium for COPD patients over 55 years of age and never-smokers, evaluate cardiovascular risk in advance and monitor closely for coronary heart disease development 4
Serious but Rare Adverse Events
- Stroke and hypertension appear to be less common with tiotropium compared to oral anticholinergic drugs 6
- Cardiac arrhythmias and cardiac ischemia may occur, though observational data suggest these are more common with inhaled anticholinergics generally 6
- Overdose effects: Accidental excessive dosing can cause refractory tachycardia requiring multiple AV nodal blocking agents for stabilization 5
Cognitive Effects
- A 2025 Canadian population-based study found a small increase in dementia risk with tiotropium versus LABA-ICS (HR 1.09), though the absolute rate increase was 2.3 per 1000 person-years and of questionable clinical importance when weighed against established benefits 7
- The as-treated analysis showed no significant association, suggesting the intention-to-treat finding may not reflect true causality 7
Overall Safety Profile
- Tiotropium demonstrates a reduced risk for overall adverse events, serious adverse events, and fatal events compared to placebo in pooled trial data 2
- The incidence of adverse events is similar to placebo except for the known anticholinergic effects 1, 2
- With over 50 million patient-years of use and more than 10 years of prescribing history, tiotropium has an extensive safety database demonstrating favorable tolerability 1